https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCT06465316&r=1
Testing Teclistamab (TECVAYLI) in Combination with Iberdomide for Relapsed or Refractory Multiple Myeloma
testingteclistamabtecvaylicombinationiberdomide
https://www.gesundheitsinformation.de/teclistamab-tecvayli-bei-fortgeschrittenem-multiplem-myelom.html
Teclistamab (Handelsname Tecvayli) ist seit August 2023 zur Behandlung eines multiplen Myeloms zugelassen.
teclistamabtecvaylibei
https://www.pharmacytimes.com/view/teclistamab-cqyv-with-daratumumab-and-hyaluronidase-fihj-improves-survival-in-relapsed-refractory-mm
Teclistamab combined with daratumumab and hyaluronidase shows significant efficacy in relapsed multiple myeloma, potentially redefining treatment standards.
teclistamabplusdaratumumabhyaluronidaseimproves